Abstract
Inflammatory bowel diseases (IBD) comprise ulcerative colitis and Crohn’s disease that primarily affect the colon and small intestine. IBD patients have a higher incidence of colorectal cancer (CRC) than the general population due to chronic colonic mucosal inflammation that predisposes to the development of dysplasia, the earliest form of neoplastic change in IBD and other chronic inflammatory disorders (e.g., Barrett’s esophagus). Therefore, the two demonstrated means of reducing the risk of cancer in IBD are to control inflammation and to survey for dysplasia and remove the dysplastic area, if possible.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–81. e1; quiz e13-4.
Monstad I, Hovde O, Solberg IC, B AM. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014;27(2):95–104.
Crohn BB, Rosenberg H. Sigmoidoscopic picture of chronic ulcerative colitis. AM J Med Sci. 1925;170:20–8.
Morson BC, Pang LS. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut. 1966;8:423–34.
Bansal P, Sonnnberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterology. 1996;91:44–8.
Collins Feldman M, Fortran JS. Colon cancer, dysplasia and surveillance in patients with ulcerative colitis. A critical review. N Engl j Med. 1987;316:1654–8.
Choi PM, Zelig MP. Similarity of colon cancer in crohns disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950–4.
Fogt F, Vortmeyer AO, Goldman Giordano TJ, et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis associated dysplasia and carcinoma. Hum Pathol. 1998;9(14):31–6.
Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohns disease and ulcerative colitis are associated with elevated standardized mortaliyt ratios: a meta-analysis. Inflamm Bowel Dis 2013;19(3):599–613. This large meta-analysis of 35 articles showed that patients with UC and CD have higher rates of death from all causes, colorectal-cancer, pulmonary disease, and nonalcoholic liver disease.
Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–47.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23(8):1097–104.
Asklinrig A, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–62.
Velayos FS, Lofus Jr EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case control study. Gastroenterology. 2006;130:1941–9.
Winther KV, Jess T, Langholz E, Munkholm BV. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088–95.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639–45. This meta-analysis of population based cohort studies showed that UC increases the risk of CRC 2.4-fold. Male sex, young age at diagnosis with UC, and extensive colitis increase the risk.
Soderlund S, Brandt L, Lapidus A, Karlen P, Brostrom O, Lofberg R, et al. Decreasing time-trends of colorectal cancer in large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7.
Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med. 2000;14:145–53.
Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.
Rutter S, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal cancer in ulcerative colitis. Gastroenterology. 2004;126:4510459.
Sandborn WJ, Hanauer S, Van Assche G, Panes J, Wilson S, Patersson J, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel disease. J Crohns and Colitis. 2014;8:927–35. his review article points out that as treatment goals in inflammatory bowel diseases are evolving beyond the control of symptoms, monitoring for objective evidence of inflammation using endoscopy, cross-sectional imaging or laboratory biomarkers may be a useful approach in inflammatory bowel diseases.
Rubin DT, Kugliak CN. Using a Treat-to-Target management strategy to improve the doctor-patient relationship in inflammatory bowel disease. Am J Gastroenterol. 2015;110:1252–6. This paper emphasize the importance of the patient in deciding treatment choices and monitoring of response.
Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–22.
Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356–63.
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9. same as reference 12.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105.
Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22.
Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45(12):969–77. This paper discusses the endoscopic and histological findings and the limitations of the endoscopic and histological indices as a basis for a standardized diagnosis of mucosal healing.
26. Rubin D, Djordjevic A, Huo D, Yadron N Hanauer S.Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis.Abstract.DDW May2003
Lashner BA, Provencher KS, Seider DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterol. 1997;112:29–32.
Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107(12):1879–87.
Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.
Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
Provençale, Kowdley KV, Arora S, Wong JB. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology. 1995;109(4):1188–96.
Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2015;13(2):322–9. Data from 6823 patients with IBD (2764 with a recent colonoscopy, 4059 without a recent colonoscopy) seen and followed up for at least 3 years at 2 tertiary referral hospitals showed that recent colonoscopy (within 36 months) is associated with a reduced incidence of CRC in patients with IBD, and lower mortality rates in those diagnosed with CRC.
Kulaylat MN, Dayton MT. Ulcerative colitis and cancer. J Surg Oncol. 2010;101:706–12.
Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14(11):931–68.
Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.
Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23.
Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418–24.
Eaden JA, Mayberry JF. Guidelines for screening and surveillance of symptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10–2.
Rubib CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predict future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;100:1611–20.
Eaden JA, Ward BA, Mayberry JF. How gastroenterologist screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc. 2000;51:123–8.
Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53:256–60.
Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007;132:874–82.
Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39:216–21.
van den Broek FJ, Fockens P, van Eeden S, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomized comparison of high-resolution endoscopy and auto fluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut. 2008;57:1083.
Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103(9):2342–9.
Matsumoto T, Nakamura S, Jo Y, et al. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol. 2003;98:1827–33.
Marion JF, Waye JD, Israel Y, Present DH, Suprun M, Bodian C, et al. Chromoendoscopy Study Group at Mount Sinai School Of Medicine. Chromoendoscopy is more effective than standard colonoscopy in detecting dysplasia during long-term surveillance of patients with colitis. Clin Gastroenterol Hepatol. 2015;S1542-3565(15):01597–9. In a prospective study of 68 patients with inflammatory bowel diseases, chromoendoscopy (CE) was superior to random biopsy or white light endoscopy (WLE) analyses in detecting dysplasia in patients with colitis during an almost 28-month period. A negative result from CE examination was the best indicator of a dysplasia-free outcome, whereas a positive result was associated with earlier referral for colectomy.
Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004.
Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334–9.
van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy. 2011;43:108–11.
Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol. 2011;23:680–9.
Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol. 2012;107:885–90.
Kiesslich R, Neurath MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41(2):291–302. This paper shows that chromoendoscopy can guide biopsies and clearly reduce the amount of biopsies needed per patient to detect dysplasia. The number needed to treat is 14 panchromoendoscopy to detect 1additional patient with dysplasia.
Tanaka S, Hayashi N, Oka S, Chayama K. Endoscopic assessment of colorectal cancer with superficial or deep submucosal invasion using magnifying colonoscopy. Clin Endosc. 2013;46(2):138–46.
Laine L, Kallenbach T, Barkum A, et al. SCENIC: international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;8(13):489–501.
Laine L, Kallenbach T, Barkum A, et al. SCENIC: guidelines development panel. Gastroenterol. 2015;148(3):639–51. A meeting of IBD experts and major shareholder reviewed recent evidence that lead to a consensus statement stating that most dysplasia in IBD patients is visible and suggested how surveillance colonoscopies for detection of dysplasia should be performed and how identified dysplasia should be managed.
Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. 2015;148(3):462–7. This commentary accepts that the Scenic consensus provide good evidence to suggest chromoendoscopy(CE) be the standard for CRC surveillance in IBD patients but they caution that the many practical issues with CE and the lack of longitudinal data may limit the acceptance of CE for surveillance as standard of care.
The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003; 58:S3–S43
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Prevention and Early Detection
Rights and permissions
About this article
Cite this article
Baidoo, L., Hanauer, S.B. What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease?. Curr Colorectal Cancer Rep 12, 345–351 (2016). https://doi.org/10.1007/s11888-016-0339-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11888-016-0339-0